@Alf107 I expect bisantrene for AML is worth $500m, which is about $3 from the Market Cap close for yesterday.
So unless there's a partnership for cardio (meaning dilution and additional sales potential) and / or FTO research ($$$) ... the MC for AML points to $2.75-3.
Sure it "could" be worth more but after four years believing, let's just say it'd be nice to be wrong. We have now seen these guys in action corporately, "they couldn't organise a piss-up-in-a-pub" is a term that comes to mind - let's see what "Strategy 102" looks like lol
Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-175
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.78 |
Change
0.025(1.43%) |
Mkt cap ! $298.0M | |||
| Open | High | Low | Value | Volume |
| $1.82 | $1.82 | $1.78 | $18.81K | 10.50K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1830 | $1.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.78 | 800 | 1 |
View Market Depth
| Last trade - 10.20am 10/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |